Discover, Advance & Action Emerging RNA Therapeutics to
Optimize Treatment for the CNS

With recent approvals of oligonucleotides for Duchenne Muscular Dystrophy, the discovery of innovative new drug delivery platforms, and investment pouring into neuromuscular and neurodegenerative diseases with RNA therapeutics growing; the door to therapeutic opportunity of novel ASO, RNAi, and other RNA therapeutics for CNS disorders is wide open.

The 1st Oligonucleotides for CNS Summit brought together pioneering pharma, innovative biotech, and KOLs of academia across disciplines to discuss the chemistry of oligonucleotides in the context of CNS biology to harness the potential of oligonucleotide therapeutics for neurodegenerative and neuromuscular disorders.

From overcoming extra-hepatic delivery challenges to translating preclinical successes into appropriate clinical paradigms, this Summit took a deep dive into the seminal research that’s propelling oligonucleotide therapeutics forward in 2022 and beyond.

Download the 2021 full event guide here